Information  X 
Enter a valid email address

Nuformix PLC (NFX)

  Print      Mail a friend

Tuesday 02 March, 2021

Nuformix PLC

Research Results

RNS Number : 7841Q
Nuformix PLC
02 March 2021
 

Nuformix plc

("Nuformix", the "Company" or the "Group")

 

Nuformix Reports Results from Preliminary Preclinical Study for NXP002 (inhaled tranilast) in an ex-vivo model of IPF

 

Cambridge, UK - 2 March 2021:   Nuformix plc (LSE:NFX), a pharmaceutical development company and drug re-purposing specialist, announces results from a preliminary preclinical study that evaluated NXP002, a proprietary and new physical form of tranilast discovered by Nuformix, in combination with therapies used as standard of care (SOC) in the treatment of idiopathic pulmonary fibrosis (IPF).

 

The study, performed in collaboration with the Newcastle Fibrosis Research Group, a top level multi-disciplinary research group of Newcastle University, UK, examined both the anti-fibrotic and anti-inflammatory potential of NXP002 in combination with the current SOC therapies, pirfenidone or nintedanib, using human precision cut lung slices taken from a single IPF donor.

 

The preliminary data from this study shows that the combination of NXP002 with SOC provided strong evidence of additional effects compared to either SOC alone on both fibrotic and inflammatory markers. In addition, the results showed evidence of similar or better activity of lower doses of SOC in combination with NXP002, compared to higher doses of SOC alone, indicating a potential for a dose-sparing effect of the combination. These data supplement the previously reported study of NXP002 in the same preclinical model where positive effects were seen when NXP002 was dosed alone and now there is strong data in combination with SOC therapy.

 

Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."  

 

Dr Anne Brindley, CEO of Nuformix, said: "IPF is a devastating disease with few treatment options and there is a real need for new therapies that are efficacious but that have better tolerability than the current therapies on the market. IPF is likely to become a combination market in the future. The results of this ex-vivo study in IPF are very encouraging and suggest the potential benefit of using NXP002 in combination with standard of care treatments for IPF. These results underpin NXP002's potential and demonstrate that further development of NXP002 for the treatment of IPF is warranted."

 

Enquiries:

 

Nuformix plc

Dr Anne Brindley, CEO

Fleur Wood, Investor Relations

Email: [email protected]

 

 

 

+44 (0)1223 627222

 

 

 

Allenby Capital Limited

Tim Sohal / Matt Butlin (Sales and Corporate Broking)

Nick Athanas (Corporate Finance)

 

 

+44 (0)203 328 5656

 

About NXP002 (inhaled tranilast) - Inhaled therapy for Fibrotic Diseases

Nuformix's NXP002 is the Group's lead asset and proprietary new form of tranilast, being developed as a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF). Delivery of drugs to the lung by inhalation, for the treatment of respiratory diseases has potential to provide efficacy but with a reduction in side-effects compared to systemic treatment.

 

About IPF

IPF is a devastating, progressive disease caused by scarring (fibrosis) in the lung. It is a disease that affects around three million people worldwide1, including 130,0002 in the US and is designated as an Orphan Indication. Currently approved antifibrotic drugs are only partially effective in slowing disease progression and are associated with significant side effects that limit dosing and their full potential for efficacy. Thus there is an unmet need for additional therapies for patients with improved efficacy and better side effect profiles.

 

[1] https://pubmed.ncbi.nlm.nih.gov/29052582/ ;

[2] https://www.ajmc.com/view/overview-idiopathic-pulmonary-fibrosis-evidence-based-guidelines-recent-developments-treatment-landscape

 

About Nuformix

Nuformix is a pharmaceutical development company with a pipeline of assets for fibrosis and oncology. It is   focused on unlocking the therapeutic potential and value of known drugs by repurposing them and developing them into novel and differentiated medicines and, in doing so, creating additional commercial opportunities. The model of repurposing is enabled by Nuformix's expertise in the discovery of new forms of known drugs that allow Nuformix to file patent applications and get patent protection for its assets.

 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information, please visit www.nuformix.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RESUPUMUWUPGPWG

a d v e r t i s e m e n t